Objective
Exploiting our knowledge of tumour immunology and genetic technology to treat cancer is now a realistic possibility. Already, adoptive transfer of tumour-specific T cells can successfully treat some malignancies. To extend this to other cancers and to simp lify the process for clinical use, Engineered T cells (gene modified T cells artificially endowed with anti-cancer specificity) have been developed. Tumour targeting can be achieved with molecules based on T-cell receptors or on antibody fragments and the genetic constructs can also incorporate additional molecular machinery to enhance cytotoxicity, proliferation, survival, tumour homing or other features to increase anti-neoplastic activity. Partners in this IP have demonstrated key scientific aspects of t hese novel approaches and are now testing them in proof-of-concept clinical trials. The ATTACK project will optimise the technology and enhance understanding of the molecular mechanisms involved in tumour evasion of immune control to develop improved T cel l mediated immunotherapy. The partners include experts in engineered T cells and authorities in key aspects of basic immunology and tumour biology. Expertise in tumour models is critical for substantiation of the activity and for testing the different targ eting technologies, the effects of cell selection / expansion methodology and the survival / homing of the adoptively transferred effector T cells as well as safety of the improved methods. The ATTACK partners have a long record of EU based collaboration a nd the synergies between them combined with a co-ordinated approach will facilitate greater scientific understanding and enable delivery of optimised Engineered T-cell therapy. The partners own key patents in this and related fields and both commercial an d academic partners have a strong track record of clinical trial development based on scientific and technological progress. Co-ordination will be aided by an International Advisory Board of external experts.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback.
You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Call for proposal
FP6-2004-LIFESCIHEALTH-5
See other projects for this call
Funding Scheme
IP - Integrated ProjectCoordinator
MANCHESTER
United Kingdom
See on map
Participants (16)
REHOVOT
See on map
5201 ROTTERDAM
See on map
PARIS
See on map
AMSTERDAM
See on map
BERLIN
See on map
COLOGNE
See on map
EDINBURGH
See on map
PARIS
See on map
DEBRECEN
See on map
LONDON
See on map
ROZZANO - MILAN
See on map
BERGISCH GLADBACH
See on map
OXFORD
See on map
HAIFA
See on map
MADRID
See on map
MILAN
See on map